MedTrace Logo

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

NCT00417833 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-06-03

No results posted yet for this study

Summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Conditions

  • Diabetic Proliferative Retinopathy
  • Vascular Vein Oclussion
  • Choroidal Neovascularization

Interventions

DRUG

Intravitreal Bevacizumab

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Myrian L Hernández, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417833 on ClinicalTrials.gov